Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDP therapy
- Development stage
- Preclinical
- Lead developer
- Repair Biotechnologies
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Repair Biotechnologies is developing a gene therapy based on its proprietary Cholesterol Degrading Platform (CDP) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The therapy utilizes lipid nanoparticle (LNP) delivery of messenger RNA (mRNA) to provide cells with the ability to safely degrade excess intracellular free cholesterol. This intracellular cholesterol is toxic to cells and is a primary driver of the pathology and liver fibrosis associated with MASH. In preclinical studies using high-fat diet mouse models, the CDP LNP-mRNA treatment demonstrated up to a 44% reduction in liver fibrosis measures over eight weeks. As of March 2024, the company has received favorable pre-IND feedback from the FDA for the treatment of liver disease.
- Other names
- Cholesterol Degrading Platform therapyCDP LNP-mRNA
02
Targets
Fc (Antibody Fc region)
Beyond the preview
Go deeper on CDP therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDP therapy.